FAQ
Investor Relations
Where are BriaCell's corporate headquarters located?
Corporate Office - Canada
Suite 300 - Bellevue Centre, 235 -15th Street,
West Vancouver, BC V7T 2X1
Tel: 604-921-1810
Fax: 604-921-1898
Corporate Office - USA
2929 Arch Street, 3rd Floor
Philadelphia, PA 19104
Tel: 1-888-485-6340
Fax: 424-245-3719
Where is BriaCell incorporated?
BriaCell Therapeutics Corp., registered in the State of Pennsylvania as a foreign corporation formed in Delaware.
When is BriaCell’s fiscal year?
July 31
Which exchanges are BriaCell’s stocks and warrants traded at?
Nasdaq: BCTX, BCTXW, BCTXZ
TSX: BCT
Which company is BriaCell's transfer agent?
Transfer Agent & Registrar
Computershare Investor Services
100 University Ave., 8th Floor, North Tower
Toronto, ON M5J 2Y1, Canada
1-800-564-6253 (Toll free in Canada & the US)
514-982-7555 (International direct dial)
Fax: 1-888-453-0330
How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?
Computershare Investor Services
100 University Ave., 8th Floor, North Tower
Toronto, ON M5J 2Y1, Canada
1-800-564-6253 (Toll free in Canada & the US)
514-982-7555 (International direct dial)
Fax: 1-888-453-0330
Which company is BriaCell's auditor?
MNP
Which firms are legal counsels to BriaCell?
Sichenzia Ross Ference Carmel LLP
1185 Avenue of the Americas, 31st Floor
New York, NY 10036
Telephone: (212) 930-9700
Bennett Jones LLP
3400 One First Canadian Place
P.O. Box 130
Toronto, Ontario
M5X 1A4 Canada
T: 416.863.1200
F: 416.863.1716
Where can I get the latest corporate news releases, investor presentation, and financial reports?
How can I view documents BriaCell has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q?
A current copy of BriaCell’s annual report and proxy can be found here or available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
Who makes up BriaCell’s Management team and Board of Directors?
Whom should I contact regarding investor inquiries?
Investor inquiries can be directed to investors@briacell.com.
Which Analysts track BriaCell?
Emily Bodnar of H.C. Wainwright & Co.
Ashok Kumar, PhD, CFA of ThinkEquity
How can I obtain a copy of your annual report and proxy?
A current copy of BriaCell’s annual report and proxy can be found here or available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov.
When and where will BriaCell hold its next annual meeting?
We anticipate BriaCell will hold its annual meeting in January of each year; please refer to the Filings & Shareholder Info in the Investor Section of our website here.
What does BriaCell do?
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. A primary focus for the company right now is treatments for metastatic breast cancer (MBC). Current therapies in development include Bria‑IMT™ and Bria‑OTS™. Bria-IMT™ is currently in Phase 3 clinical trials and has received a Fast Track designation from the FDA.
The company positions itself as an innovative immuno-oncology firm in the biotech industry. It aims to expand beyond breast cancer to develop therapies for prostate cancer and other types of cancer.
Bria-OTS™ is in a Phase 1/2 clinical study and is a personalized off-the-shelf cell-based immunotherapy. The drug has two mechanisms: it works directly by stimulating T-cells and indirectly by producing GM-CSF and antigens to help train the T-cells to identify cancer cells and destroy them.
What stage is BriaCell’s lead therapy, Bria‑IMT™, in?
Bria‑IMT™ is currently in a pivotal Phase 3 clinical study in Advanced Breast Cancer, termed Bria-ABC™, and has been awarded Fast Track status by the FDA. The Bria-ABC™ study evaluates Bria-IMT in combination in an immune check point inhibitor in MBC patients (NCT06072612). It is being regularly reviewed by the independent Data and Safety Monitoring Board (DSMB), which to date has recommended study continuation without safety concerns.
BriaCell’s Phase 2 clinical study showed that Bria-IMT™ regimen resulted in ~2X longer progression free survival and overall median survival in late-stage MBC patients who have failed other treatment options compared to comparable patients in other studies. No Bria-IMT™ treatment-related discontinuation has been reported to date.
Is BriaCell publicly traded?
BriaCell is traded on Nasdaq (BCTX, BCTXW, BCTXZ) and the Toronto Stock Exchange (BCT). Current prices and historic price charts are provided on our Stock Information page.
What is the outlook for BriaCell’s stock?
As a clinical-stage biotech company, BriaCell's stock performance is closely tied to the progress of clinical trials and regulatory events. This is true for any immunotherapy stocks that are pre-market. We provide information about current trials in our investor presentations and publish regular news releases about new products, regulatory changes, and clinical trial progress.
Does BriaCell publish investor presentations or earnings reports?
Yes, BriaCell investor presentations and earnings reports can be found on our investor relations pages. You can also find copies of our slide decks, details of recent investor calls, analyst reports, and other news that may be of interest to investors. To get updates on the latest news, sign up for our email alert service. We'll deliver the latest company updates directly to your inbox, so you're always in the know.
Where can I find SEC filings and financial reports?
BriaCell's filings and financial reports are published online on EDGAR and SEDAR. You can find links to our filings, AGM minutes, and other information relevant to investors on our shareholder information page. We also provide links to recent analyst coverage, news and events, and corporate fact sheets, as well as updates on the progress of our research and clinical trials.
Who are BriaCell’s partners and advisors?
BriaCell works with several medical and scientific partners and has a diverse advisory team that includes experienced medical advisors such as Dr. Brufsky, a leading Professor of Medicine at the University of Pittsburgh School of Medicine, and Dr. Christofanilli, the Chief of Breast Medical Oncology at the Sandra and Edward Meyer Cancer Center.
The scientific advisory team includes experienced immunologists and researchers in the world of pharmacology, and cancer biology. Together, these experts have contributed to BriaCell's research on innovative treatments for breast cancer, prostate cancer, and other conditions. In addition, BriaCell is partnered with Prevail InfoWorks, who provide technical assistance with several aspects of our clinical trial management.
How does Bria‑IMT™ work?
Bria-IMT is an off-the-shelf immunotherapy that's designed to stimulate the body's own immune response against breast cancer cells. It is being evaluated in a Phase 3 combination study for metastatic breast cancer, after having been awarded fast-track status by the FDA.
Bria-IMT activates the immune system to target breast cancer cells, including those that have spread to other tissues, and helps the body destroy those cells, offering hope for those who have been diagnosed with this aggressive form of cancer.
How can I stay updated on BriaCell news?
You can stay up-to-date with BriaCell news by visiting the News and Events page in the Investor Relations section of the BriaCell website. You can also subscribe to our email list to receive investor alerts, so you're always up-to-date on our latest products and innovations.